Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes

被引：0
|
作者：
Edmonston, Daniel
Mulder, Hillary
Lydon, Elizabeth
Chiswell, Karen
Lampron, Zachary
Shay, Christina M.
Marsolo, Keith
Bosworth, Hayden B.
Pagidipati, Neha
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-912-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
912-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Shah, Raj C.
    Jones, W. Schuyler
    Gordon, Howard
    Hwang, Wenke
    Ayoub, Isabella
    Ford, Daniel
    Chamberlain, Alanna
    Rao, Ajaykumar
    Fonseca, Vivian
    Chang, Alexander
    Ahmad, Faraz
    Hung, Adriana
    Hunt, Kelly
    Butler, Javed
    Bosworth, Hayden B.
    Pagidipati, Neha
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 696 - 708
  • [2] Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes
    Neuen, Brendon L.
    Solomon, Scott D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 709 - 711
  • [3] Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1566): : 26 - 28
  • [4] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    [J]. AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
  • [5] Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in patients with type 2 diabetes and moderate chronic kidney disease
    Rossing, P.
    Fioretto, P.
    Clark, A.
    Jensen, A. B.
    Nazal, N. Belmar
    Tuttle, K. R.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S356 - S357
  • [6] Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
    Scheen, Andre J.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 143 : 88 - 100
  • [7] The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes
    Azoulay, Laurent
    Simms-Williams, Nikita
    Yin, Hui
    Lu, Sally
    Treves, Nir
    Yu, Oriana Hoi Yun
    [J]. DIABETES, 2023, 72
  • [8] GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura
    Baroni, Marco Giorgio
    [J]. DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 193 - 212
  • [9] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Nagahisa, Taichi
    Saisho, Yoshifumi
    [J]. DIABETES THERAPY, 2019, 10 (05) : 1733 - 1752
  • [10] Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes
    Taichi Nagahisa
    Yoshifumi Saisho
    [J]. Diabetes Therapy, 2019, 10 : 1733 - 1752
12345